**REVIEW**

**Autosomal dominant polycystic kidney disease: recent advances in clinical management [version 1; peer review: 2 approved]**

Zhiguo Mao¹, Jiehan Chong²,³, Albert C. M. Ong²,³

¹Kidney Institute of CPLA, Division of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai, China
²Kidney Genetics Group, Academic Nephrology Unit, University of Sheffield Medical School, Sheffield, UK
³Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

**Abstract**

The first clinical descriptions of autosomal dominant polycystic kidney disease (ADPKD) go back at least 500 years to the late 16th century. Advances in understanding disease presentation and pathophysiology have mirrored the progress of clinical medicine in anatomy, pathology, physiology, cell biology, and genetics. The identification of **PKD1** and **PKD2**, the major genes mutated in ADPKD, has stimulated major advances, which in turn have led to the first approved drug for this disorder and a fresh reassessment of patient management in the 21st century. In this commentary, we consider how clinical management is likely to change in the coming decade.

**Keywords**

autosomal dominant polycystic kidney disease, ADPKD, PDK1, PDK2, clinical management

---

**Open Peer Review**

**Reviewer Status**

Invited Reviewers

<table>
<thead>
<tr>
<th>Invited Reviewers</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>version 1</strong></th>
<th>✓</th>
<th>✓</th>
</tr>
</thead>
<tbody>
<tr>
<td>published</td>
<td>18 Aug 2016</td>
<td></td>
</tr>
</tbody>
</table>

**F1000 Faculty Reviews** are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the reviewers are listed below, but their reports are not formally published.

1. **Jared J Grantham**, University of Kansas Medical Center, Kansas City, USA
2. **Vicente Torres**, Mayo Clinic, Rochester, USA

Any comments on the article can be found at the end of the article.
Corresponding author: Albert C. M. Ong (a.ong@sheffield.ac.uk)

Competing interests: ACMO has served as a consultant to the Otsuka Corporation (Tokyo, Japan) on advisory boards and was a site investigator for the TEMPO3/4 and OVERTURE studies. JC has received educational travel support from the Otsuka Corporation. ZM declares that he has no competing interests.

Grant information: Work in the authors’ laboratories was supported by the Chinese Society of Nephrology (#13030340419), National Natural Science Foundation of China (#81570621), National Institutes for Health Research, Kidney Research UK (RP40/2014), ERA-EDTA, and the EU (EU-FP7/2007-2013, grant agreement #317246, TranCYST).

Copyright: © 2016 Mao Z et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Mao Z, Chong J and Ong ACM. Autosomal dominant polycystic kidney disease: recent advances in clinical management [version 1; peer review: 2 approved] F1000Research 2016, 5(F1000 Faculty Rev):2029 (https://doi.org/10.12688/f1000research.9045.1)

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease worldwide and the fourth most common cause of end-stage renal disease (ESRD). It is a significant economic health burden to societies, and annual costs of providing renal replacement therapy (RRT) within the European Union (EU) are estimated at 1.2 billion euros. The median age of ESRD for patients with ADPKD within the EU is 58 years and has shifted only slightly over the past two decades (1991–2010) with the acceptance of older patients onto RRT programmes. The management of ADPKD, long considered an untreatable disease, is undergoing a major paradigm shift with regulatory approval of the first effective drug for delaying disease progression. In this review, we consider some of the major recent advances that have led to this shift in clinical management.

Prevalence, natural history, and clinical presentation

Estimates of the prevalence of ADPKD vary widely depending on the population studied, methodology used, and local screening policy. Within the EU, ADPKD is now considered to fulfil the definition of a rare disease (less than 1 in 2,000 affected) and has implications for health policy and funding. This issue is still debated (asymptomatic cases may be undiagnosed without comprehensive screening of at-risk family members), but the definition probably applies to symptomatic cases.

The diagnostic uncertainty, especially early in disease, reflects the natural history of the condition with a long phase of stable renal function (glomerular filtration rate, or GFR) followed by a steep linear decline late in the course of disease (Figure 1). The latent phase of disease, especially in the early years, masks subtle changes in kidney physiology and the often silent but progressive expansion in kidney size. Studies in children with ADPKD reveal glomerular hyperfiltration, microalbuminuria, loss of urinary concentration, and loss of the normal diurnal blood pressure rhythm as early subclinical manifestations.

Depending on the health system, patients may opt to undergo cascade screening or may present with typical symptoms (urinary tract infection, macroscopic haematuria, renal pain, or kidney stones) at different ages. A significant proportion of at-risk individuals remain asymptomatic, being diagnosed incidentally or through the detection of hypertension or reduced GFR. Often ignored are psychological symptoms reflective of concern and loss of hope about the future (risk of inheriting the disease, uncertainty about the timing, and options for delaying ESRD) as well as inter-personal issues (guilt about transmitting the condition to the next generation) which impact individual quality of life.

Diagnostic modalities and genetic testing

Mutations in two genes, \(PKD1\) and \(PKD2\), have been found in over 90% of patients with ADPKD, and no mutations have been detected in 8% to 10%. Evidence of a third gene, \(GANAB\), was recently reported, although this accounts for only a small number of these \(PKD1\) and \(PKD2\) mutation-negative patients. In these patients, the renal phenotype was mild and the extent of liver disease was highly variable. It seems likely that incorrect ascertainment, mutations in promoter regions, or mutations in other unidentified genes could account for the rest.

In large published series, the percentage of patients with \(PKD2\) mutations ranges from 10.5% to 22%. This is very likely to reflect criteria for patient referral and selection, including their stage of kidney function. In recent data obtained from the PKD mutation database (accessed 22 April 2016), 81% and 19% of curated patients had \(PKD1\) and \(PKD2\) mutations, respectively. Although all mutation types have been reported for both genes, it is striking that only 10% of \(PKD2\) mutations were missense (compared with 27% of \(PKD1\)). This could reflect the under-diagnosis of milder asymptomatic cases of \(PKD2\) present in the general population.

Although the two ADPKD proteins have been shown to function as a heterodimeric complex, patients with \(PKD2\) have milder disease and the median age of ESRD is between 20 and 25 years later than that for \(PKD1\) for reasons that are still unclear. This has contributed to diagnostic uncertainty, especially when radiological methods were used in younger patients (under 40 years). Newer ultrasound diagnostic criteria have been published which extend the previous criteria (Ravine et al.) restricted to those at 50% risk of inheriting \(PKD1\) to those with \(PKD2\) or without a positive family history. In addition, magnetic resonance imaging criteria applying to those with a negative or uncertain family history have been published.

Where diagnostic uncertainty remains, mutation analysis for both genes is becoming routine despite the technical challenge of
analysing PKD1. Within the National Health Service (UK), testing is currently restricted to several patient groups for whom diagnostic certainty is clinically helpful. These include the need to exclude risk in potential living related kidney donors, those with atypical disease or a negative family history, rare cases of very early onset disease (less than 1%) in which the recurrence rate is high for subsequent pregnancies, and in pre-natal or pre-implantation diagnosis. Traditional Sanger sequencing is being rapidly replaced by newer approaches using next-generation sequencing (NGS) techniques. The first uses long-range polymerase chain reaction to selectively amplify the PKD1 transcript (and not those arising from the six PKD1 homologous genes, or HGs). The second has used a bioinformatics approach to distinguish sequence reads from genomic DNA unique to PKD1 from the HG loci. As the cost of testing falls, it is likely that these NGS methods will transform the use of testing for both diagnostic and prognostic purposes. A list of laboratories world-wide offering mutation analysis for PKD1 and PKD2 can be found on the GeneTests website.

**Prognostic prediction and scores**

The known individual phenotypic variability of disease and recent availability of a potential effective treatment have stimulated efforts to derive an accurate prognostic score that could be clinically useful. Two main prognostic models have been proposed. The Mayo Classification relies on age-banded height-adjusted total kidney volume (TKV)\(^3\), whereas the PROPKD score\(^2\) relies on genotype and the age of onset of clinical symptoms. Although the two scores have not been directly compared, they have their relative merits. The Mayo Classification distinguishes two classes of disease (1 typical and 2 atypical) on the basis of a retrospective analysis of a historical cohort of 590 patients seen at a single centre. Class 1 could be further subdivided into five subclasses (A to E) on the basis of the measured historical rate of kidney growth (on serial magnetic resonance or computed tomography), which in turn correlated with the rate of estimated GFR (eGFR) decline in the test population. This simple classification was then shown to have predictive value in both internal (n = 162) and external (n = 173, Consortium for Radiologic Imaging Study of PKD or CRISP) validation cohorts. Patients in class 1C–E were shown to have more rapidly progressive disease (>3 ml/min per year) than those with class 1A and B. The PROPKD score combined genotype, gender, and an age cut-off (< or >35 years) of onset of urinary symptoms or hypertension on the basis of a cross-sectional study of the Genkyst cohort, a population of 1,341 patients from Brittany. On the basis of these criteria, the authors propose three groups of patients with low, intermediate, or high risk for progression to ESRD.

The advantage of the Mayo Classification is the ability to predict prognosis on the basis of a single TKV measurement. The authors also propose that TKV can account for individual differences related to genotype as well as non-allelic factors. This study was based on a population with preserved initial eGFR (median 75 ml/min per
For imaging, issues of access, speed, and accuracy of analysis\textsuperscript{25,26} as well as harmonisation of accepted standards at a national and international level will be needed. For genotype-based scoring, further refinement of the ‘strength’ of non-truncating mutations through bioinformatics\textsuperscript{15}, family studies\textsuperscript{14}, or experimental approaches\textsuperscript{27,28} could increase its predictive value. The added value of other novel biomarkers\textsuperscript{29-31} to improve the performance of both models will need to be formally tested.

**Treatment options**

The approval of tolvaptan by regulatory authorities in Europe and around the world (though not in the USA) for use to slow renal disease progression in ADPKD patients with preserved renal function and evidence of rapidly progressive disease marks a major step-change in the management of this condition. This decision follows the pivotal TEMPO3/4 trial showing significant benefits of treatment on the rate of change in TKV as well as the decline in eGFR\textsuperscript{32}. However, the eligibility criteria for prescribing tolvaptan do vary between countries where approval has been granted (Table 1). The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Renal Association have issued more detailed guidance as to what constitutes ‘evidence of rapid disease progression’ so that treatment is offered to patients who are at the highest risk of developing ESRD and therefore potentially the ones to benefit\textsuperscript{33}. The decision pathway published by the Renal Association for the UK is shown in Figure 3 (http://www.renal.org/guidelines/commentary-on-nice-guidelines#sthash.OrPI3wDL.yCJcc9PF.dpbs). It is clear that the risks and benefits of taking tolvaptan will need to be carefully considered, especially the need for monthly monitoring of liver function tests and the profound aquaretic side-effects requiring high water intake on a daily basis.

A number of other drugs, including somatostatin analogues and tyrosine kinase inhibitors, are currently being tested in clinical trials\textsuperscript{34}. Potentially, these could be used in combination with tolvaptan if combined efficacy can be shown clinically as in preclinical models. Many other dietary and therapeutic agents have been shown to have efficacy in preclinical models, although the salutary experience with mammalian target of rapamycin (mTOR) inhibitors has demonstrated the potential divergence between preclinical results and clinical trials\textsuperscript{35,36}. The experience gained from published trials will improve patient selection, harmonise outcome measures, and likely improve future trial design\textsuperscript{1}.

**Table 1. Eligibility criteria for the approved use of tolvaptan according to country or region.**

<table>
<thead>
<tr>
<th>Country</th>
<th>Chronic kidney disease stage</th>
<th>Disease activity</th>
<th>Regulatory body</th>
<th>Approval date</th>
<th>Guidance (if any)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>1–4</td>
<td>TKV &gt;750 ml, ΔTKV &gt;5% per annum</td>
<td>Pharmaceuticals and Medical Devices Agency</td>
<td>March 2014</td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>Not specified</td>
<td>Not specified</td>
<td>Health Canada</td>
<td>February 2015</td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>1–3</td>
<td>Evidence of rapid disease progression</td>
<td>European Medicines Agency</td>
<td>May 2015</td>
<td>European Renal Association-Eurasian Dialysis and Transplant Association</td>
</tr>
<tr>
<td>England, Wales, and Northern Ireland</td>
<td>2–3</td>
<td>Evidence of rapid disease progression</td>
<td>National Institute for Health and Clinical Excellence (NICE)</td>
<td>October 2015</td>
<td>Renal Association</td>
</tr>
<tr>
<td>South Korea</td>
<td>1–3</td>
<td>Evidence of rapid disease progression</td>
<td>Ministry of Food and Drug Safety/Health Insurance Review and Assessment Service</td>
<td>December 2015</td>
<td></td>
</tr>
<tr>
<td>Scotland</td>
<td>1–3</td>
<td>Evidence of rapid disease progression</td>
<td>Scottish Medicines Consortium</td>
<td>January 2016</td>
<td>Renal Association</td>
</tr>
</tbody>
</table>

TKV, total kidney volume.
Figure 3. Recommended decision pathway for UK patients considered for treatment with tolvaptan according to Renal Association guidance based on the NICE decision. NICE has recommended that autosomal dominant polycystic kidney disease patients in England with chronic kidney disease stages 2 or 3 and evidence of rapidly progressive disease are eligible for treatment. This decision differs from that made by the Scottish Medicines Consortium and the European Medicines Agency in excluding patients with chronic kidney disease stage 1. Evidence of rapid disease progression has been defined as a significant decline in estimated glomerular filtration rate or increase in total kidney volume or both. In the absence of such evidence, risk prediction algorithms based on total kidney volume (Mayo Classification) or genotype (PROPKD) are the best predictors of prognosis. NICE, National Institute for Health and Clinical Excellence.

A new pathway for managing ADPKD in clinical practice

The rapid progress from gene discovery and understanding of pathophysiology to the first effective treatment for slowing disease progression is changing the management paradigm for ADPKD and stimulating the development of a new patient pathway (Figure 4). Ideally, this should take the form of a multidisciplinary approach beyond measuring renal function and blood pressure. It should consider the management of extra-renal complications (often neglected), which often can give rise to refractory and worrying symptoms. Family members who are at risk of inheriting the disease should be counselled and offered screening. Psychological and interpersonal issues, including ‘genetic guilt’ (of passing the disease on), are often silent and need to be explored at an early stage. Patients would benefit from joining local support groups or being part of a patient organisation. Accurate information (clinical, genetic, dietary, or therapeutic) is critical and may be best delivered through nursing or medical staff with expert knowledge. All patients should be offered initial evaluation in specialist PKD clinics with follow-up in secondary or primary care as appropriate to the individual.
Figure 4. A recommended multidisciplinary stepped pathway for managing patients with autosomal dominant polycystic kidney disease. For simplicity, this has been drawn as a linear follow-up pathway with the major emphasis being on diagnosis, prognosis and treatment at sequential visits. A shared care model with primary care physicians after full evaluation is complete and no treatment planned is an option in nationally funded systems. eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; US, ultrasound.

Many patients (though not all) will wish to be assessed for their eligibility for drug treatment or enrolment in clinical trials. Guidelines for managing patients are being developed in different countries\[40–42\].

**Conclusions**
The management of ADPKD, once considered an untreatable disease, is undergoing a major paradigm shift with more accurate diagnostics, prognostic scoring, and availability of new disease-modifying drugs. This in turn is stimulating a reshaping of patient pathways and the reorganisation of clinical services. A continued focus on developing new therapeutics and renewed attention to patient-centred research priorities are likely to alter the long-term management of ADPKD for patients and their families.

**Competing interests**
ACMO has served as a consultant to the Otsuka Corporation (Tokyo, Japan) on advisory boards and was a site investigator for the TEMPO3/4 and OVERTURE studies. JC has received educational travel support from the Otsuka Corporation. ZM declares that he has no competing interests.

**Grant information**
Work in the authors’ laboratories was supported by the Chinese Society of Nephrology (#13030340419), National Natural Science Foundation of China (#81570621), National Institutes for Health Research, Kidney Research UK (RP40/2014), ERA-EDTA, and the EU (EU- FP7/2007-2013, grant agreement #317246, TranCYST).

**Acknowledgements**
We are grateful to Lee Baker for his expert help in redrawing Figure 3 and Figure 4 and to members of the Renal Association Working Group on Tolvaptan in ADPKD for helpful discussions related to Figure 3.

**References**


Open Peer Review

Current Peer Review Status: ✔️ ✔️

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the reviewers provide input before publication and only the final, revised version is published. The reviewers who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The reviewers who approved this article are:

Version 1

1 Vicente Torres
   Department of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

   Competing Interests: No competing interests were disclosed.

2 Jared J Grantham
   , Kidney Institute, University of Kansas Medical Center

   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com